SCHEMBL3752007

SCHEMBL3752007

CNC(=O)C1c2cc(F)ccc2C(=O)N1[C@H](C)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 6/20 0.55
TSHR P16473 2/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
BRD4 O60885 4/20 0.39
GRM7 Q14831 1/20 0.39
PSEN1 P49768 3/20 0.38
PSEN2 P49810 3/20 0.38
APH1B Q8WW43 3/20 0.38
NCSTN Q92542 3/20 0.38
APH1A Q96BI3 3/20 0.38
PSENEN Q9NZ42 3/20 0.38
P2RX7 Q99572 1/20 0.38
SPPL2A Q8TCT8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757690 0.89 KCNA5 (0.53) KCNA5TSHRHTTL3MBTL1
SCHEMBL3760228 0.88 KCNA5 (0.53) KCNA5TSHRHTTL3MBTL1GRM7
SCHEMBL3749096 0.86 KCNA5 (0.55) KCNA5TSHRHTTL3MBTL1BRD4
SCHEMBL3754015 0.86 KCNA5 (0.77) KCNA5TSHRP2RX7
SCHEMBL3750647 0.82 KCNA5 (0.54) KCNA5TSHRHTTL3MBTL1PSEN1
SCHEMBL3756535 0.80 KCNA5 (0.64) KCNA5TSHRP2RX7
SCHEMBL3750314 0.78 KCNA5 (0.48) KCNA5TSHRHTTL3MBTL1GRM7
SCHEMBL3760166 0.76 KCNA5 (0.48) KCNA5TSHRHTTL3MBTL1P2RX7
SCHEMBL3752643 0.76 KCNA5 (0.81) KCNA5TSHRHTTL3MBTL1PSEN1
SCHEMBL3758325 0.75 KCNA5 (0.61) KCNA5TSHRHTTL3MBTL1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885TSHR 1287/4885HTT 3361/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885TSHR 1483/4885HTT 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.